|
 The Medicines Company expects in the 3rd Quarter
of 2012 the sale of two Russian factories, reported during half-year press conference
at august 08 by the
chairman Hartmut Retzlaff. A signature-mature contract provides
for the sale of subsidiaries Stada Pharmaceuticals Makiz OOO,
Moscow, and OOO Skopin Pharmaceutical Plant, Ryazanskaya obl,
under a partial management buy-outs prior to the DMN Invest LLC,
Moscow.
This step is part of the restructuring of a company-wide cost
efficiency program launched "Stada - build the future".
This creates an income for Stada charge of approximately € 9
million before taxes and 7.2 million euros after tax, which in
the 3rd Quarter is reported as a special effect. The financial
burden is lower than what is provided for the Russian production
restructuring.
The manufacturing of products that are currently produced in the
two Russian factories for the Stada Group, were transferred
successively until probably the end of 2014 in Russia's existing
Stada other production facilities.
Utilization and cost structure of new production facilities will
be improved, the company promises. In the transition period run
supply and service contracts further. Completion of the contract
terms and the transition of the two Russian companies for the
4th Quarter of 2012 provided.
Through the sale is a more objective met, within the "STADA -
build the future" program, about 10 percent of the workforce of
2010, which are 800 full-time positions throughout the Group to
reduce by 2013. In the two russian factories standing
before handing over 182 full-time manufacturing jobs have been
cut.
|
